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Erythropoietin (Epo) is a pleotropic cytokine with several nonhematopoietic tissue eﬀects. High-dose Epo treatment-mediated
eﬀects on body weight, fat mass and glucose tolerance have recently been reported, thus extending its pleotropic eﬀects to fat and
glucose metabolism. However, the exact dose range of Epo treatment required for such eﬀects remains unidentiﬁed to date. We
investigated Epo dosage eﬀect (up to 1000U/kg) on hematocrit, body weight, body composition, glucose metabolism, food intake,
and physical activity, during high-fat diet-induced obesity. We report that Epo doses (1000, 600, 300, and 150U/kg) signiﬁcantly
reduced body weight gain and fat mass, while, only Epo doses of 300U/kg and higher signiﬁcantly aﬀected glucose tolerance. None
o ft h et e s t e dE p od o s e ss h o w e da n yd e t e c t a b l ee ﬀects on food intake, and only 1000U/kg dose signiﬁcantly increased physical
activity, suggesting that these parameters may only be partially responsible for the metabolic eﬀects of Epo treatment.
1.Introduction
It is estimated that, worldwide, there are approximately one
billion overweight and obese people, conditions associated
with the metabolic syndrome and increased morbidity,
mortality and economic costs [1, 2]. The metabolic syn-
drome is aconstellation ofdisorders thatinclude atherogenic
dyslipidemiaandbloodpressureelevationaswellasimpaired
glucose metabolism and insulin resistance that are believed
to precede the development of type 2 diabetes [2–5].
Considering the impact of obesity and type 2 diabetes
on the health and well-being of the human population,
identifying molecular regulators of body weight, fat mass,
and glucose metabolism becomes a necessary step toward a
better understanding of the underlying mechanisms of such
conditions and devising novel therapeutic approaches.
Erythropoietin (Epo), discovered for its indispensable
role during erythropoiesis, is a glycoprotein hormone clin-
ically used for the treatment of anemia, mostly in chronic
kidney disease [6, 7]. Epo levels become elevated during
hypoxia in response to the activation of hypoxia-inducible
factor (HIF) pathway [8–10]. It is produced in the fetal
liver and adult kidney, and signals via its receptor (EpoR),
a member of the cytokine receptor I superfamily [11].
Considering that EpoR expression has been detected in
nonerythroid cells including endothelial cells, epicardium,
and brain neuroepithelium [12–14], it is not surprising that
Epo treatment can exert several nonhematopoietic eﬀects,
among which, its tissue protective eﬀects in heart and brain
injuries have been well documented [15–17].
Recent studies implicate Epo signaling in the regulation
of body weight, fat mass, and glucose metabolism [18, 19].
For instance, overexpression of Epo in mouse skeletal muscle
resulted in reduced body weight and adipose tissue mass
and the normalization of insulin levels and glucose tolerance
in high fat-fed mice [18]. Similarly, an Epo expressing
transgene in mice improved glucose tolerance and insulin
sensitivity [19]. Collectively, these observations strongly
suggest that the nonhematopoietic eﬀects of Epo may extend
to encompass the regulation of fat and glucose metabolism,
thereby implicating its signaling as a regulator of glucose
tolerance and possibly insulin sensitivity.
Todate,theexactdoserangeofexogenousEpotreatment
required for the induction of improved and/or optimal2 Journal of Biomedicine and Biotechnology
metabolic parameters, namely, reduced body weight gain,
decreased fat mass accumulation, and higher glucose tol-
erance remains unidentiﬁed. Moreover, it is still unknown
whether decreased food intake, increased physical activity,
and/or increased hematocrit are entirely responsible for such
eﬀects of Epo treatment. Prompted by the aforementioned
questions, we investigated the eﬀects of titrated Epo doses
(1000, 600, 300, 150, 75, and 0U/kg) on hematocrit, body
weight gain, body composition, glucose metabolism, food
intake and physical activity during high-fat diet-induced
obesity. As expected, hematocrit appeared to be Epo dose
dependent. To our surprise, high (1000U/kg), medium (600
and 300U/kg), and low (only 150U/kg) Epo doses signiﬁ-
cantlyreducedbodyweightgainandfatmass.Thisreduction
in body weight gain and fat mass was not associated with
decreased food intake for any of the tested Epo doses and
associatedwithincreasedphysicalactivityonlyfor1000U/kg
group. Most interestingly, high and medium Epo doses
(1000, 600, and 300U/kg) resulted in signiﬁcantly increased
glucose tolerance in association with a dose-dependent
decrease in fasting blood glucose levels, meanwhile, with the
exception of 75U/kg, all other Epo doses (150, 300, 600,
and 1000U/kg) resulted in a signiﬁcant reduction of serum
insulin levels. Collectively, our ﬁndings show, for the ﬁrst
time, that medium dose of Epo (600 and 300U/kg) can
regulate body weight, fat mass, and glucose metabolism with
no detectable changes in food intake or physical activity,
thereby suggesting the involvement of other pathways in
the regulation of Epo-mediated metabolic eﬀects. However,
it remains unknown whether decreased food intake and/or
increased physical activity are entirely responsible for such
eﬀects of Epo treatment, perhaps due to subtle changes at
levels below the detection threshold.
2.MaterialsandMethods
2.1.AnimalsandReagents. 5-6-week-oldmaleC57BL/6mice
(Fredrick, MD) were housed under speciﬁc pathogen-free
conditions in the Animal Facility of the National Institute
for Diabetes, Digestive and Kidney Diseases, Bethesda,
MD. All animal protocols were conducted under the NIH
guidelines and approved by the institute’s Animal Care and
Use Committee. Mice were maintained in a thermo-stated
environment under a 12-hour light/dark cycle with free
access to food and drinking water. Mice were fed high-
fat diet containing 60kcal% fat (high fat, 5240kcal/kg,
34.9% crude fat) (Research Diets, Inc., New Brunswick,
NJ) and separated into diﬀerent groups based on Epo dose
(n = 8mice/group). Recombinant human Epoetin alpha
(Epogen) (Amgen, Thousand Oaks, CA) was administered
subcutaneously every other day using the following doses:
1000, 600, 300, 150, and75U/kg for5weeks, withsaline only
injected mice as sham controls. In addition, mice fed low-
fat diet containing 10kcal% fat and injected with saline only
were used as normal diet controls.
2.2. Hematocrit Measurements. At the end of the study (i.e.,
Week5),hematocritwasmeasuredforallmice.Brieﬂy,blood
was collected from the tail using heparin coated capillary
tubes which were then centrifuged and used to measure
hematocrit with VIN microhematocrit capillary tube reader
(Veterinary Information Network Bookstore; Davis, CA).
2.3. Body Weight and Composition Measurements. To assess
the eﬀect of Epo treatment on body weight gain and body
composition, mice in all groups were weighed weekly, while
body composition analysis was performed at the end of
the study at week 5 using EchoMRI-100 system (Echo
Medical Systems, Houston, TX). The changes in body weight
are expressed as body weight gain (g), and changes in
body composition expressed as fat and lean mass (g) were
calculated using ﬁnal measurements (week 5) compared to
the initial measurements (Day 0) prior to the study onset.
2.4. Glucose Tolerance Test. A tw e e k5 ,a l lm i c ew e r ef a s t e d
for 16 hours and challenged with an intraperitoneal load
of glucose (2g/kg). Blood glucose of conscious mice was
measured at 0, 15, 30, 60, 90, and 120 minutes after
glucose administration using code 7 AlphaTRAK glucometer
(Abbott Animal Health, Abbott Park, Illinois). Basal blood
glucose readings (i.e., at time 0) are fasting blood glucose
measurements.
2.5. Serum Insulin Measurements. Blood was collected at
week 5 before fasting, and serum insulin was measured
using Sensitive Rat Insulin Radioimmunoassay (RIA) Kit
(Millipore, St. Charles, Missouri).
2.6. Food Intake Measurements. To assess the eﬀect of Epo
treatment on food intake, mice (n = 6/group) were ﬁrst
adapted to individual caging (one mouse/cage) for 1 week,
after which were each given 100g of food pellets every week.
Food intake for each mouse per group was determined by
measuring the weight of remaining food pellets every 48hrs.
2.7. Physical Activity Measurements. To assess the eﬀect
of Epo treatment on physical activity, total activity of
each mouse (n = 6/group) as measured by beam breaks
per minute and locomotor activity as measured by total
movement episodes per minute (episodes are separated by
a rest period of at least 1 second) were determined at the
end of the study period (i.e., week 5) by employing AccuScan
Instruments Inc manufactured machine and the operating
software Fusion 2.2.
2.8. Statistical Analysis. Results are expressed as the mean
± SEM. ANOVA single-factor test was used for statistical
analyses during intergroup comparisons. Values of P ≤ .05
were considered statistically signiﬁcant.
3. Results
3.1. Epo Treatment and Hematocrit. The most pronounced
and commonly characterized eﬀect of exogenous Epo treat-
ment is the resulting elevated hematocrit. As expected, we
found that the measured increase in hematocrit directly
reﬂectedEpodosageafter5weeksofsubcutaneousinjections
(Figure 1). There was a statistically signiﬁcant diﬀerenceJournal of Biomedicine and Biotechnology 3
0
10
20
30
40
50
60
70
80
90
H
e
m
a
t
o
c
r
i
t
(
%
)
∗∗
∗∗
∗∗ ∗∗
1000 600 300 150 75 Sham
control
Normal
diet
Epo:
(U/kg)
Figure 1: Hematocrit increase is directly reﬂective of Epo dose
treatment. C57BL/6 male mice (6wks of age) were put on 60%
high fat diet and received exogenous Epo treatment of the following
doses (1000, 600, 300, 150, and 75U/kg) injected subcutaneously,
three times a week; high-fat diet and control diet fed mice injected
with saline only were used as sham and normal diet controls,
respectively (n = 8mice/group). At the end of the study (i.e.,
week 5), hematocrit was measured for all mice, and the results are
expressed as the mean of ﬁnal % hematocrit ± SEM. ANOVA single
factor test was used for statistical analysis; values of P ≤ .05 were
considered statistically signiﬁcant.
in hematocrit levels of 1000, 600, 300, and 150U/kg
Epo treatments which were 73.8%, 68.5%, 63.5%, and
61.5%, respectively, when compared to sham control 54.5%
(Figure 1); meanwhile, there was no diﬀerence between the
hematocrit levels of 75U/kg Epo-treated group and the
sham control which were 56% versus 54.5%, respectively
(Figure 1). Therefore, Epo treatment dose ranges were
designated as follows: 1000U/kg as high, 600 and 300U/kg
as medium, and 150 and 75U/kg as low Epo doses.
3.2. High, Medium, and Low Epo Dose Treatments Reduced
Body Weight Gain and Fat Mass. To identify Epo dose
range required for reducing body weight gain and fat mass
accumulation, we investigated the eﬀects of titrated Epo
doses (1000, 600, 300, 150, and 75U/kg) on body weight
gain and body composition (i.e., fat versus lean mass) during
high-fat diet-induced obesity. C57BL/6 male mice (6wks of
age; n = 8mice/group) were put on 60% high fat diet and
received exogenous Epo treatment, injected subcutaneously,
three times a week. At week 5, body weight gain and
composition were determined for all groups and compared
to lean and overweight mice injected with saline only as
sham and normal diet controls, respectively. Treatment of
mice with high dose Epo (1000U/kg) resulted in signiﬁcant
r e d u ct i o ni nb o d yw e i gh tg a i n4 .78±0.352g when compared
to saline-treated controls (i.e., sham control) 9.44 ± 1.09g
(Figure 2(a); P = .001). The reduced weight gain observed
in mice on 600 and 300U/kg Epo was (5.21 ± 1.05g
and 5.18 ± 0.356g, resp.) (Figure 2(a); P = .02 and.01).
Meanwhile, of those on lower dose Epo (150 and 75U/kg),
only the 150U/kg group showed signiﬁcant diﬀerence in
body weight gain (5.4 ± 0.285g) when compared to sham
controls (Figure 2(a); P = .01). As expected, none of the Epo
dose treatments used caused any detectable changes in lean
body mass during body composition analysis (Figure 2(b)).
Overall, the eﬀect of high (1000U/kg), medium (600
and 300U/kg), and low (only 150U/kg) Epo doses on the
reduction of body weight gain was statistically signiﬁcant,
comparedwithnoEpoShamcontrol(Figure 2(a)).Similarly,
when body composition analysis was performed in compar-
ison to sham control, we found doses that reduced body
weight gain, to also cause fat mass reduction (Figure 2(c)).
Interestingly, 300U/kg Epo treatment resulted in a tendency
toward lower fat mass accumulation than higher Epo doses
of 600U/kg and 1000U/kg; however, this diﬀerence was not
found to be statistically signiﬁcant (Figure 2(c)). Thus, not
only high (1000U/kg) but also medium (600 and 300U/kg)
and low (150U/kg) Epo doses can also regulate body weight
and fat mass.
3.3. Epo Treatment and Glucose Metabolism. Glucose tol-
erance is an indirect indicator for insulin sensitivity and
healthy pancreatic islets β-cell response. As previously
mentioned, recently reported evidence using high-dose Epo
treatmentandconstitutiveoverexpressionsystemsimplicates
Epo in the regulation of blood glucose [18, 19]. Thus, to
assess the eﬀects of Epo doses (1000, 600, 300, 150, and
75U/kg) on glucose tolerance during obesity, C57BL/6 male
mice (6wks of age; n = 8/group) were put on 60% high-
fat diet and injected subcutaneously with the indicated doses
of exogenous Epo, three times a week for 5 weeks. At the
end of the study (i.e., week 5), glucose tolerance test (GTT)
was performed for all groups in comparison to lean and
overweightmicethatreceivedsalineinjectionsascontrols.As
expected, mice treated with medium and high Epo doses of
300, 600, and 1000U/kg showed signiﬁcantly higher glucose
tolerance than no Epo sham control (Figure 3(a); P = .002).
Consistentwiththeobservedeﬀectsonbodyweightgainand
fat mass, Epo dose (75U/kg) did not show any diﬀerence in
glucose tolerance compared to sham controls (Figure 3(a)).
In contrast, despite the obvious eﬀects of 150U/kg Epo dose
onbodyweightgainandfatmassreduction(Figures2(a)and
2(c)), this Epo dose caused no detectable change in glucose
tolerance compared to sham controls (Figure 3(a)).
To gain more insight into the observed diﬀerential eﬀects
for medium and high versus low Epo doses on glucose
tolerance (Figure 3(a)), we compared the levels of fasting
blood glucose and nonfasting serum insulin of all groups to
sham control. We observed an inverse correlation between
medium and high Epo doses (300, 600, and 1000U/kg)
and fasting blood glucose levels, which was found to be
dose dependent, and signiﬁcantly diﬀerent from that of the
sham control (Figure 3(b); P = .04, .03 and .01, resp.).
Meanwhile, although treatment with low Epo doses (75
and 150U/kg) did not cause signiﬁcant reduction in fasting
blood glucose, we observed a tendency toward a similar
trend between Epo dose and blood glucose (Figure 3(b)).
Interestingly, Epo treatment with all doses tested, with the
exception of 75U/kg, resulted in signiﬁcant reduction of
serum insulin levels (Figure 3(c)). These ﬁndings collectively4 Journal of Biomedicine and Biotechnology
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Figure 2: Epo treatment and body weight gain and composition. C57BL/6 male mice (6 wks of age) were put on 60% high fat diet and
received exogenous Epo treatment of the following doses (1000, 600, 300, 150, and 75U/kg) injected subcutaneously, three times a week
(n = 8mice/group). At week 5, body weight gain (a) and body composition; lean mass (b) and fat mass (c) were determined for all groups
and compared to lean and overweight mice injected with saline only as sham and normal diet controls, respectively. Results are expressed as
the mean ± SEM. ANOVA single-factor test was used for statistical analysis; values of P ≤ .05 were considered statistically signiﬁcant.
indicate that the involvement of Epo treatment in the
regulation of glucose metabolism is not restricted to its high
dose range.
3.4. Eﬀects of Epo Treatment on Food Intake and Physical
Activity. Since changes in food intake and physical activity
greatly inﬂuence body weight and composition, we assessed
whether or not Epo doses found to signiﬁcantly reduce
body weight gain and fat mass, namely, (150, 300, 600,
and 1000U/kg; Figures 2(a) and 2(c)) can change these
parameters. Comparing all groups to each other and to
sham controls, we found no detectable change in food
intake (Figure 4(a)). Results from activity measurements as
determined by beam breaks per minute showed signiﬁcantly
increased total activity to be exclusive for the 1000U/kg Epo
dose-treated group (Figure 4(b); P = .03). It is noteworthy,
however, that despite the lack of statistical signiﬁcance in
the diﬀerence between Epo doses lower than 1000U/kg
compared to sham control, there is an overall trend of
increasing physical activity with increasing Epo dose. This
was also found to be the case for locomotor activity results as
measured by total movement episodes per minute (episodes
are separated by a rest period of at least 1 second; data
not shown). Linear regression analysis for total physical
activity of all mice on high fat diet receiving sham and
Epo treatment (0, 150, 300, 600, 1000U/kg) was also
performed and showed that R2 = 0.3124 (Figure 4(b) inset).
Collectively, it was concluded that, at least for this study’s
period, Epo treatment causes detectable changes in physical
activity only at 1000U/kg dose, thereby suggesting thatJournal of Biomedicine and Biotechnology 5
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Figure 3: Epo-mediated improvement of glucose metabolism. C57BL/6 male mice (6wks of age) were put on 60% high-fat diet and received
exogenous Epo treatment of the following doses (1000, 600, 300, 150, and 75U/kg) injected subcutaneously, three times a week; high-fat diet
and control diet fed mice injected with saline only were used as sham and normal diet controls, respectively (n = 8mice/group). Glucose
tolerance test (a) was performed at week 5 after study onset; all mice were fasted for 16 hours and challenged with an intraperitoneal load
of glucose (2g/kg). Blood glucose was measured at 0, 15, 30, 60, 90, and 120 minutes after glucose administration. The eﬀects of diﬀerent
Epo dose treatments on fasting blood glucose (b) and serum insulin (c) were also assessed. The results are expressed as the mean ± SEM.
ANOVA single-factor test was used for statistical analysis; values of P ≤ .05 were considered statistically signiﬁcant.
changes in physical activity only partly explain the observed
metabolic eﬀects of Epo treatment. However, whether or
not lower Epo doses (600, 300, and 150U/kg) can also
regulate body weight gain and fat mass by aﬀecting physical
activity, perhaps at levels below the detection threshold for
the current technology, remains to be further investigated.
4. Discussion
High-fat diet-induced obesity mouse model is a well-
characterized model that has been widely used to study
diet-induced obesity and its associated insulin resistance
[2, 18, 19] and thus makes a suitable system to study the
eﬀects of exogenous Epo dose titration on body weight gain
and glucose tolerance. Although, high-dose exogenous Epo
treatment has been reported to reduce body weight and
improve glucose tolerance, there is no information about the
exact dose range of Epo treatment required for the reduced
body weight gain, fat mass accumulation, and improved
glucose tolerance. Moreover, it is still unclear whether such
eﬀects of Epo treatment are inﬂuenced by changes in food
intake and/or physical activity. In this study, using high-
fat diet-induced obesity model, we report that Epo doses
ranging from 300 to 1000U/kg administered subcutaneously
every 48hrs for a period of 5 weeks resulted in reduced
body weight gain and fat mass, improved glucose tolerance,6 Journal of Biomedicine and Biotechnology
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Figure 4: The eﬀects of Epo treatment on food intake and physical activity. C57BL/6 male mice (6 wks of age) were put on 60% high-fat diet
and received exogenous Epo treatment of the following doses (1000, 600, 300, 150, and 75U/kg) injected subcutaneously, three times a week
(n = 6 mice/group). After adapting to individual caging (i.e., one mouse per cage) for one week, the eﬀects of Epo treatment on food intake
(a) and physical activity (b) were determined for all groups and compared to lean and overweight mice injected with saline only as sham
and normal diet controls, respectively. Results are expressed as the mean ± SEM. ANOVA single-factor test was used for statistical analysis;
values of P ≤ .05 were considered statistically signiﬁcant. Figure 4(b) inset summarizes the results of the linear regression analysis for total
activity of all mice on high-fat diet receiving sham or Epo treatments (0, 150, 300, 600, and 1000U/kg).
decreased serum insulin, and reduced fasting blood glucose
(Figures 2 and 3). Lower Epo dose of 150U/kg signiﬁcantly
reduced body weight gain and fat mass, and decreased serum
insulin, with no detectable eﬀects on fasting blood glucose or
glucose tolerance,meanwhile75U/kg Epo dose did not show
any change in these parameters (Figures 2 and 3).
Our ﬁndings with high-dose Epo (1000U/kg) are in
agreement with recent studies reporting reduction of body
weight gain and blood glucose in a human Epo transgenic
mouse model (tg6), and as a result of very high-dose Epo
treatment (180U/mouse compared with 25U/mouse for
high dose injection used here) using the leptin deﬁcient
(ob/ob) and tyrosine phosphatase 1B deﬁcient (PTP1B−/−)
mouse models of obesity and insulin resistance [19]. Our
results are also consistent with recent reports showing that
Epo expressed in supraphysiological levels has substantial
metabolic eﬀects including protection against diet-induced
obesity, reduced serum insulin levels, and normalization
of glucose sensitivity [18]. However, in addition to these
reports, we show that high as well as medium (600 and
300U/kg) and low (150U/kg) Epo doses can regulate body
weight, fat mass, and certain aspects of glucose metabolism.
Such distinction between high, medium, and low range of
Epo doses becomes critical, when considering the adverse
eﬀectsofhigh-Epodosetreatmentreportedinseveralclinical
studies, leading to updated recommendations for Epo use in
anemic cancer patients [20, 21].
To date, the exact mechanisms underlying Epo’s action
in regulating fat mass accumulation and glucose tolerance
remain unknown. However, considering our observations
showingthatnoneoftheEpodoseshadanydetectableeﬀects
on food intake, and only the 1000U/kg dose signiﬁcantly
increased physical activity, these data suggest that food
intake may not be involved while physical activity is only
partially involved in Epo treatment-mediated regulation of
body weight, fat mass, and glucose metabolism. To this end,
it has been suggested that a shift to increased fat oxidation
in muscle is responsible, at least in part, for the observed
normalization of glucose sensitivity with high dose Epo
[18]. Moreover, recent studies in our laboratory further
suggestthatEpo’sabilitytoinhibitadipogenesiscouldbeone
mechanism through which it can regulate body weight and
fat mass accumulation (Teng et al., unpublished data). It is
also possible that Epo aﬀects fat mass and glucose tolerance
by directly regulating lipolysis, and insulin production
and/orglucoseutilization,orbyindirectregulationofenergy
expenditure via aﬀecting metabolic rates. Further studies
to identify the exact molecular pathways underlying Epo-
mediated regulation of fat mass and glucose metabolism are
required.
It is intriguing that 300U/kg Epo treatment resulted
in a slightly more pronounced eﬀect on body fat mass
reduction and decreased serum insulin, with total activity
levels statistically indistinguishable from the sham control,
andslightlylowerthanthoseofthe1000U/kggroup(Figures
2(c), 3(c) and 4(b), resp.). A question raised here pertains
to the possibility of an optimum eﬀective dose for Epo
(300U/kg) in regulating fat mass and insulin levels. It is
conceivable that such outcome may be due to the possible
saturation of Epo receptor suggesting Epo response beyond
hematopoietic tissue. Epo saturation has been previously
reported to occur at high-Epo doses in nonerythroid cultureJournal of Biomedicine and Biotechnology 7
systems [22]. Epo receptor is expressed at lower level in
nonhematopoieticcomparedwitherythroidprogenitorcells,
and hence, a higher level of Epo may be required for
saturation of EpoR on erythroid progenitor cells. However,
the applicability of such phenomenon to in vivo situations
remains to be veriﬁed.
The link between cytokine signaling, body weight, and
fat mass accumulation for other cytokines such as TNF-α
and IL-18 on body weight and fat metabolism have been
well documented. TNF-α also known as cachectin is known
to promote lipolysis and inhibit the production of enzymes
needed to produce and store fat [23, 24]. IL-18 on the
other hand has been shown to regulate energy homeostasis
by suppressing apatite and feed eﬃciency and was strongly
associated with obesity and insulin resistance, where IL-
18 deﬁcient mice become obese and insulin resistant as a
consequence of hyperphagia [25, 26]. Most interestingly, the
molecular mechanism identiﬁed to be responsible for IL-
18-mediated regulation of food intake and gluconeogenesis
involves its ability to regulate STAT3 phosphorylation, where
it was found that STAT3 phosphorylation can inhibit food
intakeandadiposetissueaccumulation[25].Consideringthe
importanceofSTAT3activationandphosphorylationduring
Epo signaling [27] and the observed eﬀects of Epo signaling
on body weight, fat mass, and glucose tolerance, it will be
important to assess such eﬀects for Epo signaling on apatite,
body weight gain, fat mass accumulation, and glucose
metabolism in mouse models with EpoR deﬁciency in non-
hematopoietictissues,andtoinvestigatewhetherSTAT3acti-
vation and/or phosphorylation is responsible for the Epo-
mediated regulation of the indicated metabolic parameters.
5. Conclusion
In summary, we report that high (1000U/kg), medium (600
and 300U/kg), and low (150U/kg) doses of Epo are eﬀective
inreducingbodyweightandfatmassinmiceonhighfatdiet.
H i g ha n dm e d i u m ,b u tn o tl o wd o s e sr e d u c ef a s t i n gb l o o d
glucose and improve glucose tolerance, while all Epo doses,
except 75U/kg, reduce serum insulin. These eﬀects for Epo
treatment do not appear to be mediated by regulating food
intake. Moreover, since signiﬁcant changes in total activity
were only detected at 1000U/kg, it is suggested that physical
activity is likely only partially responsible for the reported
eﬀects of Epo. Collectively, these observations indicate that
the nonhematopoietic eﬀects of Epo do indeed extend to
encompass the regulation of fat and glucose metabolism and
point to the possible involvement of pathways other than
food intake and physical activity downstream of Epo.
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